Biologically Modified Saphenous Vein Transplants for Improved CABG Outcomes

  • End date
    Nov 22, 2021
  • participants needed
  • sponsor
    St. Luke's Hospital, Chesterfield, Missouri
Updated on 22 January 2021
hmg-coa reductase inhibitor


The purpose of this study is to study the effects of polyarginine treated vein grafts on graft patency for patients undergoing coronary artery bypass surgery.


Double blind study with Lactated Ringers Solution and Lactated Ringers Solution with Arginine soaked for 10 minutes prior to grafting on the coronary arteries.

Condition Atherosclerosis, Arteriosclerosis, Atherosclerotic Cardiovascular Disease
Treatment Polyarginine, Vein soak treated with Lactated Ringers Solution
Clinical Study IdentifierNCT01313533
SponsorSt. Luke's Hospital, Chesterfield, Missouri
Last Modified on22 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age between 25 yrs and 95 yrs?
Gender: Male or Female
Do you have Atherosclerosis?
Do you have any of these conditions: Atherosclerotic Cardiovascular Disease or Arteriosclerosis or Atherosclerosis?
Subjects must be 25-95 years of age and able to give informed consent
Use of an approved statin and anti-platelet medication for at least 24 months
Agreeable to Cardiovascular imaging at 12 months post-coronary artery bypass graft (CABG)
First time coronary artery bypass surgery,redo coronary artery bypass surgery and combined valve repair/replacement surgery and coronary artery bypass graft surgery are eligible to participate in study

Exclusion Criteria

Acute traumatic injury, vasculitis or planned concurrent ventricular surgical restoration, automatic implantable cardioverter defibrillators (AICD) placement or valvular surgery
Hypercoaguable state
Comorbid illness making 2 year survival unlikely
Participation in another interventional investigative study of a cardiovascular drug or device within 30 days prior to CABG. May participate concurrently in other studies where the intervention/observation will not hinder execution of this study
Patients with any medical condition that, in the investigator's judgment, makes the patient ineligible or places the patient at undue risk (e.g. conditions that preclude standard invasive follow up procedures such as angiography, i.e. renal failure, bleeding diathesis or peripheral vascular disease preventing catheterization via the groin)
Subject has clinical evidence of infection that the Investigator deems significant to the completion of the procedure or that could compromise the subject's safety
Any patient was has undergone more than 20 computerized tomography (CAT) scans
Any patient who is pregnant
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note